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Abstract
Background: Interleukin-15 (IL-15) is thought to be involved in the physiopathological mechanisms of RA and it can be
detected in the serum and the synovial fluid of inflamed joints in patients with RA but not in patients with osteoarthritis or
other inflammatory joint diseases. Therefore, the objective of this work is to analyse whether serum IL-15 (sIL-15) levels
serve as a biomarker of disease severity in patients with early arthritis (EA).
Methodology and Results: Data from 190 patients in an EA register were analysed (77.2% female; median age 53 years; 6-
month median disease duration at entry). Clinical and treatment information was recorded systematically, especially the
prescription of disease modifying anti-rheumatic drugs. Two multivariate longitudinal analyses were performed with
different dependent variables: 1) DAS28 and 2) a variable reflecting intensive treatment. Both included sIL-15 as predictive
variable and other variables associated with disease severity, including rheumatoid factor (RF) and anti-cyclic citrullinated
peptide antibodies (ACPA). Of the 171 patients (638 visits analysed) completing the follow-up, 71% suffered rheumatoid
arthritis and 29% were considered as undifferentiated arthritis. Elevated sIL-15 was detected in 29% of this population and
this biomarker did not overlap extensively with RF or ACPA. High sIL-15 levels (b Coefficient [95% confidence interval]: 0.12
[0.06–0.18]; p,0.001) or ACPA (0.34 [0.01–0.67]; p=0.044) were significantly and independently associated with a higher
DAS28 during follow-up, after adjusting for confounding variables such as gender, age and treatment. In addition, those
patients with elevated sIL-15 had a significantly higher risk of receiving intensive treatment (RR 1.78, 95% confidence
interval 1.18–2.7; p=0.007).
Conclusions: Patients with EA displaying high baseline sIL-15 suffered a more severe disease and received more intensive
treatment. Thus, sIL-15 may be a biomarker for patients that are candidates for early and more intensive treatment.
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Introduction
The optimal strategy to manage rheumatoid arthritis (RA) is
currently to start an early and intensive treatment adjusted to a
specific target [1,2,3,4,5]. However, the widespread use of
treatment with disease modifying anti-rheumatic drugs (DMARD)
in combination may expose some patients with early arthritis (EA)
to unjustified risks, while the first line use of biological agents for
non-selected patients may be not cost-effective. To overcome these
issues, it would be wise to use biomarkers capable of detecting
patients at high risk of developing a severe disease. Although
rheumatoid factor (RF), anti-citrullinated peptide antibodies
(ACPA) and some genetic factors have been associated with an
adverse evolution [6,7,8,9,10], their predictive value is still limited
[11]. Therefore, additional markers to predict outcome and
therapeutic responses are needed.
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physiopathological mechanisms of RA. These events include the
regulation of cell interactions that promote TNF production
[12,13,14], and the activation of Th17 lymphocytes driving IL17
production [15,16,17,18]. Through this latter effect, IL-15
regulates the osteoclastogenesis that contributes to juxtaarticular
osteoporosis and bone erosion [19,20,21,22]. IL-15 also modulates
the functional maturation of dendritic cells and contributes to the
survival and activation of neutrophils, B and NK cells [23,24,25].
In support of its contribution to RA pathogenesis, IL-15 can be
detected in the synovial fluid of inflamed joints in patients with RA
but not in patients with osteoarthritis or other inflammatory joint
diseases [26,27,28]. In fact, IL-15 neutralization improves arthritis
in animal models and patients with RA [29,30].
Unlike synovial fluid, serum samples are commonly used to
measure diagnostic and prognostic biomarkers. IL-15 is elevated in
the serum of some patients with RA but not in healthy controls
[15,31,32,33]. Indeed, we recently showed that measuring serum
IL-15 (sIL-15) is a potentially useful biomarker as the elevation of
this cytokine in serum is not generalized in patients with EA [34].
Therefore, considering the relevant functions of this cytokine in
RA, we aimed to test its utility as a clinical biomarker in our
register of patients with EA.
Methods
Ethics Statement
The register protocol was reviewed and approved by the Ethics
Committee for Clinical Research at the Instituto de Investigacio ´n
Sanitaria La Princesa. All patients were informed about the study
and signed an informed consent form prior to be included in the
EA Register.
Objectives
The hypothesis of this work is that patients with early arthritis
and high levels of sIL15 suffer a more severe disease. The specific
objectives were to determine whether patients with high sIL15
showed higher disease activity or had greater treatment require-
ments during their follow-up.
Participants
All the patients enrolled on our Early Arthritis Clinic (EAC)
register between September 2001 and November 2006 were
considered in this study. During this period 190 patients were
included, although only 171 patients completed the two year follow-
up (the last patient ended in November 2008). Data from 638 visits
correspondingtotheselaterpatientswereconsideredfortheanalysis.
There were 14 patients lost to follow-up and 5 exitus. Deceased
patients were significantly older, had a lower educational level and
they also displayed a tendency towards a higher HAQ and DAS28
at baseline than those who finished the follow-up (Table S1).
Patients lost to follow-up did not differ significantly from
completers (Table S1).
Our EAC covers a population of 500,000 inhabitants, .90% of
whom are attended by public health insurance. In addition, all
primary care physicians in the area are aware of the EAC. To be
referred to the clinic, patients must have two or more swollen
joints for at least four weeks and symptoms for less than a year.
Patients with other specific causes of arthritis were excluded. Thus,
only data from patients that fulfilled the ACR criteria for the
diagnosis of RA [35] or with chronic undifferentiated arthritis
were analyzed. When the 171 patients that fulfilled the two year
follow-up were considered, 71% fulfilled the 1987 criteria for RA
classification, while 29% remained as undifferentiated arthritis
(UA: Table S2) at the end of the follow-up. These two
subpopulations did not differ significantly except that the RA
patients had a more severe disease at baseline and the educational
level of the UA subpopulation was higher (Table S2).
The register’s protocol included four visits during a follow up
period of two years (baseline, 6, 12 and 24 months). At each visit,
the following data were collected and entered into an electronic
database: clinical and demographic information; disease duration
at the beginning of the follow up; 28 tender and swollen joint
counts (TJC and SJC, respectively); global disease activity on a
100 mm visual analogue scale assessed both by the patient
(GDAP) and the physician (GDAPh); Spanish version of the
Health Assessment Questionnaire [36]; and laboratory tests
including erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) and RF levels assessed by nephelometry (positive.20 UI/
ml) and ACPA measured by enzyme immune assay (EIA) (Euro-
Diagnostica Immunoscan RA; positive .50 UI/ml).
Description of procedures
1. Measurement of serum IL-15. sIL-15 was measured
using a sandwich EIA as described previously [32,34]. Cytokine
values were calculated from a standard curve and samples that
generated values higher than the highest standard were diluted
(1:1) in diluent buffer and assayed again.
Serum samples were measured for IL-15 in a blind manner
and the physicians that took the therapeutic decisions were also
blind to the sIL-15 concentration during the entire follow-up of
the patient. To increase the consistency of the results, samples
from each patient were assayed twice, the first time after one year
of follow-up (samples from the baseline, six month and twelve
month visits) and the second time at the end of the follow-up
when all four samples were analysed. The duration of frozen
storage at 280uC did not significantly altered the measurement
of sIL-15 and, therefore, the mean of the two measurements was
considered as the definitive value. The exceptions were the final
visit or if there was a variation .30% between the values from
any sample. In this latter circumstance, all samples from the
patient were re-analysed and the definitive value was the mean of
the three measurements.
The results of sIL-15 were then used into two variables: a
quantitative variable with the value of the cytokine at each visit in
pg/ml and a qualitative variable (yes/no) that referred to whether
the baseline value of sIL-15 was .20 pg/ml. This latter value was
selected as the threshold since it was previously shown to represent
the 90
th percentile in a healthy population [34].
The intra-assay coefficient of variation was 18.7633.1% (mean
6 standard deviation) and the inter-assay variability was
32.7633.7%.
2. Other variables and measurements. Disease activity
was assessed by the DAS28 based on the ESR as described
previously [37].
Regarding DMARD use, we collected the date of onset and
withdrawal to generate a new variable, ‘‘Intensity of DMARD
treatment’’ (IDT), which represents the number of days of
treatment with each DMARD during the follow-up, adjusted by
weighted coefficients as follows:
IDT=[(16 number of days with antimalarials [AM])+(1.56
number of days with methotrexate [MTX], leflunomide [LEF],
sulphasalazine, parenteral gold salts or cyclosporin A)+(26
number of days with TNF blockers [aTNF])]/number of days of
follow-up.
We also revised the patients’ GC prescription, as described
previously [38], obtaining the cumulative GC dose in mg of
prednisone/month of follow-up.
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generated two qualitative variables for which the patient was
considered to be positive if their mean DAS28 during follow-up or
IDT variable were above the 75
th percentile of the whole
population.
Statistical analysis
The sample was described in terms of mean and SD of
quantitative variables with a gaussian distribution; median and the
interquartile range (IQR) if the variables displayed a non-normal
distribution and; through an estimate of the proportions for
qualitative variables. The Student’s t test was applied to compare
the means of variables with a normal distribution and the Mann
Whitney or Kruskall-Wallis tests were used for variables with a
non-normal distribution. A x
2 or Fisher’s test were used to
compare categorical variables.
To determine which factors influenced disease activity during
the follow-up, we fitted a population-averaged model by
generalized linear models (GLM), nested by patient and visit,
using the xtgee command of Stata 10.1 for Windows (StataCorp LP,
College Station, TX, USA). The only difficulty with using
Population Averaged Generalized Estimating Equations (PA-
GEE) procedures is in understanding the correlation structure
[39]. Since the different working correlation matrices assessed did
not differ significantly, we present the data from the exchangeable
correlation structure that assessed the largest number of
observations. The PA-GEE were first modeled adding all the
variables with a p value,0.15 in the bivariate analysis. The final
models were reached by means of Quasilikelihood under the
independence model Information Criterion [40] and Wald tests,
removing all variables with p.0.05.
Risk ratios for high disease activity or high IDT were estimated
through the binreg command of Stata using the rr option. This
command fits GLM allowing adjustment for confounding factors,
and the rr option transforms the b coefficients into risk ratios. We
first included all variables with a p value,0.15 in the respective
bivariate analysis. The final models were reached by means of
Bayesian Information Criterion (BIC) removing all variables with
p.0.05 except those that provided a lower BIC value when they
were maintained in the model. The RF, ACPA and sIL-15 were
then forced in the model to establish their respective risk ratio for
each dependent variable.
Results
The elevation of sIL-15 overlaps slightly with the
presence of rheumatoid factor or anti-cyclic citrullinated
antibodies
As previously described for this population [34], we considered
increased levels of sIL-15 when higher than 20 pg/ml and the
levels detected for this cytokine ranged from undetectable to
434 pg/ml, being the median level 8.6 pg/ml (Table 1). Patients
with increased sIL-15 levels showed a slightly trend to higher
disease activity baseline measurements than those with low IL-15
levels, although differences in most of those variables did not reach
statistical significance (Table 1).
RF was detected in 43.3% of patients, ACPA in 39.3% and high
sIL-15 in 29.2% of the whole population. These three markers
were detected more frequently among the patients that fulfilled the
RA criteria than in the UA patients (Table S3). On the other
hand, none of the markers were detected in 35.7% of the patients
and we did not observe an extensive overlap of these markers,
except for the presence of both RF and ACPA, especially in
patients with RA (Figure 1 and Table S3). These data reflect the
heterogeneity among patients with EA.
Elevated sIL-15 is associated with higher disease activity
in patients with EA
The median disease activity in patients with EA tended to be
slightly higher during the follow-up in those with high sIL-15, or
with positive RF or ACPA (Figure 2A). However, these differences
were not statistically significant. Interestingly, analysis of data from
Table 1. Characteristics of the population considering the presence of high levels of IL15.
Total IL15 low IL15 high p
N (%) 171 121 (70.8) 50 (29.2)
Female (%) 133 (76.4) 97 (78.9) 36 (70.6) n.s.
Age at baseline 53 [42–66] 54 [41–67] 51 [43–62] n.s.
Educational level (%)
N–P–S-U
5 – 41 – 31 – 23 6 – 41 – 30 – 23 2 – 41 – 31 – 36 n.s.
Disease duration at baseline (months) 6 [4.2–9] 6.2 [4.5–9.3] 5.6 [3.2–8.6] n.s.
1987 RA criteria (%) 121 (70.8) 79 (65.3) 42 (84) 0.016
DAS28 at baseline 4.5 [3.3–5.7] 4.4 [3.3–5.8] 4.8 [3.5–5.3] n.s.
HAQ at baseline 1 [0.5–1.62] 1.1 [0.5–1.625] 0.875 [0.5–1.5] n.s.
Pain (mm) 48 [24–65] 50 [26–70] 39 [20–60] 0.06
GDA Physician 37 [25–50] 30 [25–50] 41 [25–60] 0.09
RF+(%) 75 (43.9) 49 (39.7) 26 (52) n.s.
ACPA+(%) 68 (38.6) 43 (35.5) 25 (50) 0.07
IL-15 (pg/ml) 8.6 [2.6–24] 5 [1–9.8] 45 [27–80] ,0.001
Data are shown as the median or percentage. N: number; Educational level N: none; P: primary school; S: secondary school; U: university. DAS28: 28-joint count Disease
Activity Score. HAQ: Health Assessment Questionnaire. GDA: global disease assessment. RF: rheumatoid factor. ACPA: anti-cyclic citrullinated peptide antibodies; RA:
rheumatoid arthritis.
doi:10.1371/journal.pone.0029492.t001
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baseline appeared to display clearly higher DAS28 than those with
low sIL-15 (Figure 2B). However, due to the small number of
patients, these differences were not significant. Moreover, such
differences were not observed when patients positive and negative
for RF or ACPA were compared (Figure S1).
Since multiple factors may introduce bias when analysing the
value of RF, ACPA or sIL-15 as markers of poor prognosis in
terms of disease activity, we performed a multivariable longitudi-
nal analysis including sociodemographic and therapeutic variables,
as well as these three markers. Accordingly, we found that female
gender and advanced age were associated with increased DAS28
scores during the follow-up (Table 2). On the other hand,
treatment with MTX, AM, LEF or aTNF were associated with a
significant improvement of disease activity in our patients. When
adjusted for all these factors, the presence of high baseline sIL-15
was significantly associated with higher DAS28 values during the
follow-up (Table 2 model 1). The b coeff. suggests 0.12 increasing
DAS28 by each 20 pg/ml increase in baseline sIL-15, then
corresponding to 2.4 points in those patients with the highest sIL-
15 levels (<400 pg/ml). Likewise, a positive ACPA but not RF
was also associated with higher disease activity. A model without
treatments showed a slightly milder yet significant association
between sIL-15 and DAS28 values (Table 2, model 2). However,
when therapeutic variables were removed from the analysis,
ACPA was no longer significantly associated (Table 2, model 2).
High sIL-15 is associated with a greater prescription of
DMARDs
The rheumatologists prescribing treatment to the patients were
blind to sIL-15 serum values during follow-up but not to their RF
or ACPA reactivity. Hence, we examined whether the presence of
these markers was associated with more intensive treatment.
The IDT during follow-up was significantly greater in those
patients with elevated sIL-15, compared with low sIL-15 (median
1.88 [IQR: 1.5–2.43] vs 1.47 [0.86–1.76]; p,0.001), or with a
positive RF (1.6 [1.4–2.27] vs 1.49 [0.82–2.1]; p=0.024) or
positive ACPA (1.61 [1.47–2.17] vs 1.45 [0.57–2.11]; p=0.034).
When the risk ratio for greater IDT was analysed, those patients
with high sIL-15 had a significantly higher risk of receiving IDT
(RR 2.38, 95% confidence interval 1.54–3.69; p,0.001; Table 3).
By contrast, the presence of RF or ACPA was not significantly
associated with a higher risk of intensive DMARD treatment
(Table 3).
We then measured the IDT in function of the different
combinations of the three markers. Patients with elevated sIL-15
seemed to have a tendency to more intensive DMARD treatment,
irrespective of the other markers (Figure 3A, grey boxes; the
Kruskall-Wallis’ test confirmed a global significant difference
among subgroups, while direct paired comparisons with the
Mann-Whitney test could not be performed due to the small
number of patients in each subgroup).
Regarding the cumulative dose of glucocorticoids, this variable
tended to be greater in patients with positive RF, ACPA or high
sIL-15, although statistical significance was not reached (Figure 3B
and Table S4).
A more detailed analysis of DMARD use showed that patients
with high sIL15 levels and those with positive ACPA were more
frequently prescribed with combined therapy and less frequently
managed without DMARDs (Figure 4A and B). However, the
presence of RF was not significantly associated with differences in
the pattern of use of DMARDs (Figure 4C). In addition, MTX
and LEF were more frequently prescribed to patients with high
sIL-15, a positive RF or ACPA (Figure 4D to F). Furthermore, the
frequency of aTNF prescription was also significantly different
when patients were sorted by sIL-15 levels or ACPA (Figure 4D
and E), although the number of patients in this situation was low
(10 patients), as expected for this type of population. There were
no significant differences in the use of antimalarials, sulphasala-
zine, gold salts or cyclosporin A (data not shown).
Figure 1. Distribution of rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (ACPA) and/or high sIL-15 levels (sIL-
15) in the population of patients with Early Arthritis. Data are shown as Venn diagrams whose circle size has been adjusted to represent,
albeit not exactly, the number of patients with each combination of markers. The raw number of patients is displayed larger than the percentages
that appear in brackets. The total number of patients is 171, although since some patients exhibited combinations of markers, the sum of the number
of patients under the name of the biomarkers exceeds this figure.
doi:10.1371/journal.pone.0029492.g001
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e29492Figure 2. Increased serum IL-15 levels are associated with more severe disease activity during the follow-up of patients with Early
Arthritis. A) Evolution of disease activity estimated by DAS28 during the follow-up period in a population of patients with Early Arthritis (EA), and in
accordance with the presence of different biomarkers. Left panel: patients with high (grey boxes; n=50) or low (white boxes; n=121) sIL-15. Middle
panel: patients with positive (grey boxes; n=75) or negative (white boxes; n=96) rheumatoid factor reactivity. Right panel: patients with positive
(grey boxes; n=68) or negative (white boxes; n=103) anti-cyclic citrullinated peptides antibodies. B) Evolution of disease activity estimated by the
DAS28 during the follow-up in patients with early Rheumatoid Arthritis (RA; n=121) or Undifferentiated Arthritis (UA; n=50) depending on the
presence of high (grey boxes) or low (white boxes) IL-15 serum levels. Data are presented as the interquartile range (p75 upper edge of the box, p25
lower edge, p50 midline in the box), as well as the p95 (upper line from the box) and p5. Dots represent the outliers. X-axis shows follow-up visits.
Visit 1: baseline; visit 2: six months; visit 3: twelve months; visit 4: twenty four months.
doi:10.1371/journal.pone.0029492.g002
Table 2. Variables related with the evolution of disease activity in patients with Early Arthritis.
Model 1 Model 2
b Coeff. [95% CI] p b Coeff. [95% CI] P
Female gender 1.0 [0.66–1.46] ,0.001 1 [0.6–1.3] ,0.001
Age at DO (by 10 year) 0.3 [0.2–0.4] ,0.001 0.3 [0.1–0.4] ,0.001
RF Positive - n.s. - n.s.
ACPA Positive 0.34 [0.01–0.67] 0.044 - n.s.
IL-15 (by 20 pg/ml) 0.12 [0.06–0.18] ,0.001 0.08 [0.02–0.14] 0.003
Methotrexate 20.74 [20.96–20.52] ,0.001 n.i. -
Antimalarial 20.48 [20.79–20.18] 0.002 n.i. -
Sulphasalazine - n.s. n.i. -
Leflunomide 20.52 [20.9–20.14] 0.007 n.i. -
Cyclosporine A - n.s. n.i. -
Gold salts - n.s. n.i. -
TNF blockers 21.33 [22.08–20.57] 0.001 n.i. -
Coeff: coefficient; CI: confidence interval; DO: disease onset; RF: rheumatoid factor; ACPA: anti-cyclic citrullinated peptide antibodies; n.s.: not significant; n.i.: not
included. Multivariable analysis model 1 includes the effect of DMARD treatment at each visit whereas in model 2, the treatment was not considered.
doi:10.1371/journal.pone.0029492.t002
IL-15 as Prognostic Biomarker in Early Arthritis
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e29492Discussion
Three relevant findings arise from this study: 1) patients with
EA and increased sIL-15 were prescribed more intensive DMARD
treatment during the two first years of the disease; 2) high levels of
IL-15 may be associated with a higher disease activity during the
follow-up; and 3) there is heterogeneity in RA regarding the
presence of prognosis biomarkers.
This study confirms our previous data reporting the more
intensive prescription of DMARDs in those patients with long
standing RA and higher sIL-15 [32]; the limitations of that
previous study included its retrospective design and the limited
number of patients. By contrast, in the current study we included
more than 170 patients prospectively followed, in which the use of
DMARDs was carefully recorded. Accordingly, we report a clear
association between high sIL-15 and the prescription of more
intensive treatment, which could be explained in several ways.
First, our findings reflect the importance of this cytokine in RA
physiopathology [12–19,22] and thus, patients with higher sIL-15
levels may suffer a more severe disease that requires more intensive
treatment. Alternatively, sIL-15 could simply be a marker
associated to other well known poor prognostic factors in RA.
Our data show that there is only partial overlap between sIL-15
and RF or ACPA, which suggests an independent role for sIL-15
as a biomarker. A third explanation could be that the
rheumatologists prescribing treatments were biased by other
factors. This is unlikely in the case of sIL-15 since physicians
were entirely unaware of the value of this parameter in the
subjects. By contrast, the association in our study of RF and ACPA
with an increased need for DMARDs could have been influenced
by the awareness among prescribing rheumatologists of these
markers and of their value as poor prognostic factors [6,7,9].
Table 3. Risk ratio of Rheumatoid Factor, Anti-cyclic citrullinated peptide antibodies and sIL-15 levels associated with a higher
mean disease activity or need for intensive treatment during the follow-up.
Mean DAS28 Intensive DMARD treatment
Risk ratio [95% CI] p Risk ratio [95% CI] p
Rheumatoid Factor + 1.13 [0.63–2.05] n.s. 1.26 [0.78–2.04] n.s.
ACPA + 1.57 [0.92–2.67] n.s. 0.91 [0.56–1.48] n.s.
sIL-15.20 pg/ml 0.92 [0.66–1.30] n.s. 2.38 [1.54–3.69] ,0.001
Female gender 2.68 [1.05–6.81] 0.039 - n.s.
Age at DO: ,40 y-o Ref. - - n.i.
40–55 1.60 [0.47–5.44] n.s. - n.i.
55–70 3.37 [1.07–10.60] 0.038 - n.i.
.70 6.50 [2.18–19.39] 0.001 - n.i.
DAS28: 28-joint count Disease Activity Score. DMARD: disease modifying anti-rheumatic drugs. CI: confidence interval. ACPA: anti-cyclic citrullinated peptide antibodies;
n.s.: not significant; n.i.: not included. DO: disease onset. Ref.: reference variable.
doi:10.1371/journal.pone.0029492.t003
Figure 3. Intensity of treatment in a population of early arthritis patients. A) Cumulative DMARD treatment during the follow-up period,
estimated through the IDT variable (see Methods), in the different subpopulations clustered by the elevated IL-15 serum levels (IL-15 h), the presence
of rheumatoid factor (RF+) and/or anti-citrullinated peptides antibodies (ACPA+). B) Distribution of the cumulative glucocorticoid dose adjusted to
the number of days of follow-up in the different subpopulations clustered by the elevated sIL-15, RF and/or ACPA. Grey boxes represent those
patients with high IL-15 alone or in combination with other biomarkers. In all panels the data are presented as the interquartile range (p75 upper
edge of the box, p25 lower edge, p50 midline in the box), as well as the p95 (upper line from the box) and p5. Dots represent the outliers. Statistical
significance was established through Kruskal-Wallis test.
doi:10.1371/journal.pone.0029492.g003
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and disease activity during the follow-up was not strong. Indeed,
this latter biomarker was not significantly associated with disease
activity assessed by DAS28, even when the analysis was adjusted
by the treatment prescribed to the patients at each visit. This may
be the consequence of the extensive overlap between ACPA
antibodies and RF, the former being a better biomarker for disease
severity than the latter. By contrast, both IL-15 and ACPA were
Figure 4. Patterns of DMARD use in a population of early arthritis patients. Left column: Proportion of patients treated with no DMARD
(None; n=17), DMARDs in monotherapy (Mono; n=75) or in combined therapy (CT; n=79) in function of the presence (grey columns) or absence
(white columns) of high serum IL-15 (A panel), anti-cyclic citrullinated peptide antibodies (ACPA; B panel) or rheumatoid factor (RF; C panel).
Statistical significance was established through Fisher’s test. Right column: Proportion of patients treated with methotrexate (MTX; n=133),
leflunomide (LEF; n=57) or tumor necrosis factor blockers (aTNF; n=10) in function of the presence (grey columns) or absence (white columns) of
high serum IL-15 (D panel), anti-cyclic citrullinated peptide antibodies (ACPA; E panel) or rheumatoid factor (RF; F panel). Statistical significance was
established through x
2 test, except in the case of aTNF use that was analysed through Fisher’s test.
doi:10.1371/journal.pone.0029492.g004
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and both contributed significantly to our statistical model when it
was adjusted to treatment. It should be mentioned, however, that
the normal tendency of the members of our unit to obtain a tight
control of disease activity is likely to have diminished the ability to
estimate the risk ratio for severe disease activity of having
elevated sIL-15, positive ACPA or RF reactivity in our
population.
Our study also highlights the heterogeneity among patients with
EA. Only ACPA and RF overlapped significantly in our
population (almost 20% of the total population) and more
importantly, .35% of patients did not display any of the
biomarkers studied here and some of them had a strong need
for treatment. This percentage increases by 10% if IL-15 is not
measured, since this is the proportion of patients in our population
with increased sIL-15 but no other biomarker. Therefore, further
efforts will be necessary to validate new biomarkers, and new
candidates may be generated by ‘‘-omics’’ studies (genomic,
transcriptomic, proteomic, metabolomic,…) that may help detect
patients that need intensive treatment promptly.
Another putative marker for bad prognosis in RA is the
presence of increased levels of acute phase reactants at disease
onset. The disadvantage of such biomarkers (ESR, CRP or even
IL6) is that many patients can be under treatment with
glucocorticoids or DMARDs when first evaluated by the
rheumatologist. However, we previously found that sIL-15 levels
do not change with treatment [34], such that sIL-15 could be used
in both naı ¨ve and treated patients. In this regard, patients with
high sIL-15 displayed increased ESR, CRP and IL6 values at their
first visit, although no differences were observed at following visits
(Figure S2).
Among the potential limitations of this study we can mention:
first, the absence of pre-established treatment strategy in our unit,
such as in the BeSt study [1], although data were exhaustively and
rigorously collected regarding DMARD treatment, including
biological agents. The rheumatologists involved in the study
largely follow the treatment recommendations of the Spanish
Society of Rheumatology for RA [5,41], considered especially pro-
active in a comparative study of RA management in different
European countries [3]. Another shortcoming is that information
about RF and ACPA reactivity was only collected as qualitative
variables; It is likely that the performance of ACPA, and especially
RF, would improve if they were managed as quantitative variables.
However, these biomarkers have been studied in depth elsewhere
and we wanted to focus on IL-15.
In summary, our data show that patients with EA and high sIL-
15 levels at baseline experience a worse disease evolution, despite
receiving more intensive treatment. If this finding were reproduced
in other populations of patients with EA, sIL-15 levels could serve
as a reliable biomarker, alone or in combination with others, to
determine which patients are candidates for more intense
treatment.
Supporting Information
Figure S1 Evolution of disease activity estimated by the
DAS28 during the follow-up in patients with early
arthritis (EA) depending on the presence of positive
(gray boxes) or negative (white boxes) Rheumatoid
Factor (RF; Upper panels) or anti-citrullinated peptide
antibodies (ACPA; Lower panels). Left panels: patients that
fulfilled Rheumatoid Arthritis criteria during the follow-up. Right
panels: patients that remain as Undifferentiated Arthritis at the
end of the follow-up. The data are presented as the interquartile
range (p75 upper edge of the box, p25 lower edge, p50 midline in
the box), as well as the p95 (upper line from the box) and p5. The
dots represent the outliers.
(TIF)
Figure S2 Evolution of interleukin 6 (IL-6) serum levels,
erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP) and swollen joint count (SJC) in patients with
early arthritis depending on the presence of high levels
of IL-15 (gray boxes) or low levels of IL-15 (white boxes).
The data are presented as the interquartile range (p75 upper edge
of the box, p25 lower edge, p50 midline in the box), as well as the
p95 (upper line from the box) and p5. The dots represent the
outliers. * p,0.05 Mann-Whitney test.
(TIF)
Table S1 Characteristics of the patients described in
the study and those who did not complete the follow-up.
F-U: follow-up; n: number; IQR: interquartile range; N: none;
P: primary school; S: secondary school; U: university; Sp:
Spanish; SA: South American; EE: Eastern European; RA:
rheumatoid arthritis; UA: undifferentiated arthritis; ACPA: anti-
citrullinated peptide antibodies; PhGDA: physician global
disease assessment.
(DOC)
Table S2 Characteristics of the population clustered by
final diagnosis. Data are shown as median or percentage. N:
number; IQR: interquartile range. Study level N: none; P: primary
school; S: secondary school; U: university. Native country S:
Spanish; SA: South American; EE: Eastern Europe. DAS28: 28-
joint count Disease Activity Score. HAQ: Health Assessment
Questionnaire. GDA: global disease assessment. RF: rheumatoid
factor. ACPA: anti-citrullinated peptide antibodies; RA: rheuma-
toid arthritis; UA: undifferentiated arthritis.
(DOC)
Table S3 Distribution of rheumatoid factor, anti-cyclic
citrullinated peptide antibodies and high levels of IL-15
in patients with Early Arthritis. RF: rheumatoid factor;
ACPA: anti-citrullinated peptide antibodies; Data are shown as the
number of patients and the percentage (%). Statistical analyses
were performed using the Fisher’s test.
(DOC)
Table S4 Use of glucocorticoids in the population of
early arthritis patients, and the subpopulation positive
for rheumatoid factor, anti-cyclic citrullinated peptide
antibodies or with high serum IL-15 levels. RF: rheuma-
toid factor; ACPA: anti-citrullinated peptides antibodies. Statistical
analyses were performed using the Kruskal-Wallis’s test.
(DOC)
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